XLO - SEC Form 4 insider transactions

SEC Form 4 filed by Director Shannon James Samuel

SEC Form 4 filed by Director Bonstein Sara

SEC Form 4 filed by Director Curran Daniel J.

SEC Form 4 filed by Director Xu Yuan

SEC Form 4 filed by Director Ross Robert W.

SEC Form 4 filed by Director Bello Akintunde Olatokumbo

SEC Form 4 filed by Director Brennan Aoife

SEC Form 4 filed by Blanchard Cheryl R

SEC Form 4 filed by Shannon James Samuel

SEC Form 4 filed by Large owner Gilead Sciences, Inc.

CHIEF MEDICAL OFFICER Luptakova Katarina converted options into 16,625 shares, increasing direct ownership by 100% to 33,250 units (SEC Form 4)

Chief Financial Officer Frankenfield Christopher James converted options into 19,375 shares and sold $4,522 worth of shares (7,030 units at $0.64), increasing direct ownership by 99% to 24,766 units (SEC Form 4)

SVP, FINANCE AND ACCOUNTING Brennan Kevin M. converted options into 5,000 shares and sold $1,174 worth of shares (1,826 units at $0.64), increasing direct ownership by 99% to 6,371 units (SEC Form 4)

PRESIDENT AND CEO Russo Rene converted options into 44,250 shares, increasing direct ownership by 16% to 325,422 units (SEC Form 4)

SEC Form 4 filed by Xilio Therapeutics Inc.

SEC Form 4 filed by SVP, FINANCE AND ACCOUNTING Brennan Kevin M.

SEC Form 4 filed by Chief Financial Officer Frankenfield Christopher James

SEC Form 4 filed by CHIEF MEDICAL OFFICER Luptakova Katarina

SEC Form 4 filed by PRESIDENT AND CEO Russo Rene

Amendment: SEC Form 4 filed by PRESIDENT AND CEO Russo Rene

SEC Form 4 filed by Director Ross Robert W.

SEC Form 4 filed by Director Brennan Aoife

SEC Form 4 filed by Director Bonstein Sara

SEC Form 4 filed by Director Curran Daniel J.

SEC Form 4 filed by Director Clancy Paul J

SEC Form 4 filed by Director Xu Yuan

SEC Form 4 filed by Director Shannon James Samuel

SEC Form 4 filed by Director Rossi Christina

SEC Form 4 filed by Director Bello Akintunde Olatokumbo

SEC Form 4 filed by Large owner Gilead Sciences, Inc.

SEC Form 4 filed by Chief Financial Officer Frankenfield Christopher James

SEC Form 4 filed by PRESIDENT AND CEO Russo Rene

Chief Financial Officer Frankenfield Christopher James converted options into 19,375 shares and sold $6,841 worth of shares (6,954 units at $0.98) (SEC Form 4)

SVP, FINANCE AND ACCOUNTING Brennan Kevin M. converted options into 5,000 shares and sold $1,774 worth of shares (1,803 units at $0.98) (SEC Form 4)

PRESIDENT AND CEO Russo Rene converted options into 44,250 shares, increasing direct ownership by 22% to 244,883 units (SEC Form 4)

CHIEF MEDICAL OFFICER Luptakova Katarina converted options into 16,625 shares (SEC Form 4)

SEC Form 4 filed by SVP, FINANCE AND ACCOUNTING Brennan Kevin M.

SEC Form 4 filed by Chief Operating Officer Frankenfield Christopher James

SEC Form 4 filed by Director Clancy Paul J

SEC Form 4 filed by Director Bonstein Sara

SEC Form 4 filed by Director Xu Yuan

SEC Form 4 filed by Director Rossi Christina

SEC Form 4 filed by Director Curran Daniel J.

SEC Form 4 filed by Director Ross Robert W.

SEC Form 4 filed by Director Shannon James Samuel

SEC Form 4 filed by Director Brennan Aoife

SEC Form 4 filed by Frankenfield Christopher James

SEC Form 4 filed by Luptakova Katarina

SEC Form 4 filed by Brennan Kevin M.

SEC Form 4 filed by Russo Rene

Atlas Venture Fund Xi, L.P. sold $640 worth of shares (1,000 units at $0.64) (SEC Form 4)

Atlas Venture Fund Xi, L.P. sold $3,600 worth of shares (4,235 units at $0.85) (SEC Form 4)

SEC Form 4 filed by Frankenfield Christopher James

SEC Form 4 filed by Luptakova Katarina

SEC Form 4 filed by Brennan Kevin M.

SEC Form 4 filed by Russo Rene

SEC Form 4 filed by Luptakova Katarina

SEC Form 4 filed by Russo Rene

SEC Form 4 filed by Frankenfield Christopher James

SEC Form 4 filed by Brennan Kevin M.